In head and neck cancer cell lines characterized by a different ability to repair the DNA double-strand breaks through HR, the effectiveness of combined irradiation and PARP-inhibitor treatment in HR-deficient cells has been evaluated [59]. This evidence concerns the gene PARP1 and head and neck cancer.